Biodexa Pharmaceuticals (BDRX) Income towards Parent Company (2013 - 2025)

Biodexa Pharmaceuticals has reported Income towards Parent Company for 13 years, with the latest figure at -$5.1 million in Q2 2025.

• Quarterly Income towards Parent Company changed N/A year-over-year to -$5.1 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$9.3 million (up 48.21% YoY) and the FY2025 annual result came in at -$8.7 million, down 104.77% from the prior year.
• Income towards Parent Company retreated to -$5.1 million in Q2 2025 per BDRX's latest filing, from -$4.2 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$3.6 million in Q4 2022 and troughed at -$9.3 million in Q4 2023.
• A 5-year average of -$5.3 million and a median of -$4.4 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2021 and 2023: Income towards Parent Company surged 80.98% in 2021, then sank 158.75% in 2023.
• Over 5 years, Income towards Parent Company stood at -$7.4 million in 2021, then surged by 51.22% to -$3.6 million in 2022, then tumbled by 158.75% to -$9.3 million in 2023, then surged by 54.3% to -$4.2 million in 2024, then declined by 19.59% to -$5.1 million in 2025.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$5.1 million, -$4.2 million, and -$9.3 million for Q2 2025, Q4 2024, and Q4 2023 respectively.